HeartLung.AI Emerges as a Leading Innovator in Cardiology with 10 Accepted ESC.26 Abstracts
Accepted studies showcase HeartLung.AI’s leadership in AI-CVD, opportunistic CT screening, Agatston 2.0, chamber volumetry, and preventive cardiology. HOUSTON, TX, UNITED STATES, May 11, 2026 /EINPresswire.com/ -- HeartLung.AI today announced …